MARKET

VRAY

VRAY

ViewRay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.44
+0.26
+4.92%
After Hours: 5.47 +0.04 +0.64% 17:50 05/17 EDT
OPEN
5.13
PREV CLOSE
5.18
HIGH
5.46
LOW
5.13
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
7.36
52 WEEK LOW
1.720
MARKET CAP
879.06M
P/E (TTM)
-7.6560
1D
5D
1M
3M
1Y
5Y
ViewRay® to Present at the Jefferies 2021 Virtual Healthcare Conference
ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Jefferies 2021 Virtual Healthcare Conference. Scott Drake, President and CEO, and Zach Stassen, CFO, will participate in a fireside chat at 11:00 a.m. Eastern Time on Thursda...
PR Newswire · 3h ago
Pura Vida Investments, Llc Buys OncoCyte Corp, Align Technology Inc, Cutera Inc, Sells Acutus ...
GuruFocus News · 5d ago
Tamarack Advisers, LP Buys Patterson Inc, CVS Health Corp, ViewRay Inc, Sells Perrigo Co PLC, ...
GuruFocus News · 5d ago
Global Radiation Oncology Market Size, Growth, Competitive Landscape, Segment Forecasts and Regional Outlook 2020 - 2027
Japan, Japan, Tue, 11 May 2021 02:30:46 / Comserve Inc. / -- Key Players: Accuray Incorporated, Elekta AB, Varian Medical Systems, C.R. Bard, Inc., IBA...
Comserve · 6d ago
Strength Seen in ViewRay (VRAY): Can Its 13.8% Jump Turn into More Strength?
ViewRay (VRAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks · 05/10 12:25
Why ViewRay's Stock Is Trading Higher Today
ViewRay (NASDAQ:VRAY) shares are trading higher after the company reported better-than-expected Q1 sales results.
Benzinga · 05/07 17:11
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021
 
Benzinga · 05/07 14:02
ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
ChemoCentryx hurt by a series of downgradesLate yesterday, ChemoCentryx (CCXI) announced its narrow win at the FDA’s expert panel meeting on the potential approval for avacopan in the treatment of
Seekingalpha · 05/07 12:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRAY. Analyze the recent business situations of ViewRay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRAY stock price target is 6.41 with a high estimate of 8.25 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 218
Institutional Holdings: 189.30M
% Owned: 117.04%
Shares Outstanding: 161.74M
TypeInstitutionsShares
Increased
32
13.70M
New
16
4.13M
Decreased
18
447.42K
Sold Out
7
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.90%
Healthcare Equipment & Supplies
-0.70%
Key Executives
Chairman/Independent Director
Daniel Moore
President/Chief Executive Officer/Director
Scott Drake
Chief Financial Officer
Brian Knaley
Chief Financial Officer
Zachary Stassen
Chief Scientific Officer
James Dempsey
Director
Phil Spencer
Independent Director
Caley Castelein
Independent Director
Scott Huennekens
Independent Director
B. Kristine Johnson
Independent Director
Brian Roberts
Independent Director
Gail Wilensky
Independent Director
Kevin Xie
Independent Director
Ted Wang
No Data
About VRAY
ViewRay Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. Its MRI system captures and displays live images in one plane, four times per second or in three planes, two times per second.

Webull offers kinds of Viewray Inc stock information, including NASDAQ:VRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRAY stock methods without spending real money on the virtual paper trading platform.